Clinical trials: Daptomycin
Sepsis
An Open Label Study to Describe the Pharmacokinetics of Daptomycin in Infants
This is a safety and pharmacokinetic study of single-dose daptomycin in infants > 48 hours and < 120 days of age with suspected systemic infections.
- Trial name
- NCT00942149
- Testing
- Daptomycin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Duke University
Bone and Joint Infection, Treated by Daptomycin
Daptomycin > 6 mg/kg/Day as Salvage Therapy in Patients With Complex Bone and Joint Infection: Cohort Study in a Regionalreference Center
The choice of antimicrobial therapy to treat complex bone and joint infections (BJI) is challenging, requiring consideration of: (i) the problem of bone diffusion; (ii) the necessity of using antimicrobials active against…
- Trial name
- NCT03209934
- Volunteers
- 43 people
- Sponsor
- Hospices Civils de Lyon
Complicated Skin and Skin Structure Infections and Bacteremia Including Right-sided Endocarditis
Safety and Efficacy Study of CUBICIN (Daptomycin) Under Conditions of Actual Use
The purpose of this study is to monitor the safety and efficacy of CUBICIN under conditions of actual use in patients who are diagnosed with complicated Skin and Skin Structure infection (cSSI) or Staphylococcus aureus bacteria…
- Trial name
- NCT01219114
- Where
- 5 sites in Philippines
- Volunteers
- 200 people
- Sponsor
- AstraZeneca
Periprosthetic Joint Infection
Preoperative Daptomycin Prophylaxis in Two-Stage Exchange Arthroplasty: A Prospective, Randomized, Double-Blinded Trial
The gold standard for treating prosthetic joint infection (PJI) is two-stage exchange arthroplasty. This includes the first stage of debridement and removal of the artificial joint, and the second stage of reimplantation of the…
- Trial name
- NCT06189885
- Testing
- Cefazolin with Daptomycin, Cefazolin with vancomycin
- Where
- Taiwan
- Volunteers
- 184 people
- Sponsor
- Chang Gung Memorial Hospital
Endocarditis, Bacterial
Daptomycin as an Adjuvant Agent in the Treatment of Enterococcal Native Valve Endocarditis.
The aim of this study is to determine the safety and efficacy of daptomycin when used as an adjuvant agent to standard care in the treatment of proven native valve Enterococcal endocarditis.
- Trial name
- NCT00401960
- Testing
- Daptomycin
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Weill Medical College of Cornell University
Skin Diseases, Infectious
Safety and Efficacy Study of Daptomycin in Pediatric Participants (1 to 17 Years-old) With Skin and Skin Structure Infections
This is a multi-center, evaluator-blinded, randomized, comparative study designed to assess the safety, efficacy, and pharmacokinetics (PK) of daptomycin in pediatric subjects ages 1 to 17 years, inclusive, with complicated skin…
- Trial name
- NCT00711802
- Testing
- Daptomycin, Standard of Care (SOC)
- Where
- 30 sites in United States, India and 1 more
- Volunteers
- 396 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Cellulitis
Study Comparing CUBICIN® (Daptomycin for Injection) With Vancomycin in Cellulitis or Erysipelas
This study is designed to investigate the difference in speed and degree of symptom resolution between daptomycin and vancomycin in subjects treated for cellulitis or erysipelas by evaluation of the following parameters: Time to…
- Trial name
- NCT00295178
- Testing
- Daptomycin, Vancomycin
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Chronic Kidney Disease, Bacterial Infection
Study of the Pharmacokinetics of Daptomycin in Children With Renal Disease
The purpose of this study is to: 1. Study the pharmacokinetics and safety of daptomycin in children on hemodialysis (HD) and peritoneal dialysis (PD). 2. Determine urine, HD and PD clearance of daptomycin.
- Trial name
- NCT01012089
- Testing
- Daptomycin
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Oklahoma
Staphylococcal Skin Infections
Daptomycin Versus Vancomycin in Participants With Skin Infections Due to MRSA
This was a real-world, prospective, open-label, multicenter study in which participants were randomized (1:1) to receive intravenous (IV) vancomycin or IV daptomycin.
- Trial name
- DAPHEOR1006 (NCT01419184)
- Testing
- Daptomycin, Vancomycin
- Where
- 26 sites in United States, Puerto Rico
- Volunteers
- 250 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Nosocomial Infection, Healthcare-associated Infection
Daptomycin Versus Vancomycin in the Treatment of Nosocomial or Healthcare-associated MRSA Bacteremia
Hypothesis: The use of daptomycin to treat nosocomial or healthcare-associated bacteremia due to methicillin-resistant S. aureus (MRSA) would increase the proportion of patients whose blood cultures are sterilized after 72 hours…
- Trial name
- DAVASAB (NCT01515020)
- Testing
- vancomycin monotherapy, daptomycin monotherapy
- Where
- France
- Volunteers
- 10 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Staphylococcal Infections
Daptomycin With Rifampin for Treatment of Staphylococcal Prosthetic Joint Infection
To determine the outcome and safety of a combined antimicrobial treatment involving daptomycin and surgical approach involving retention or short-interval two-stage exchange of the implant.
- Trial name
- Dapto-Studie (NCT01144000)
- Testing
- Daptomycin
- Where
- 3 sites in Switzerland
- Volunteers
- 60 people
- Sponsor
- Andrej Trampuz
Renal Failure
Daptomycin Study - Collection of Pharmacokinetic Samples in Patients With Renal Failure
This will be a prospective, multicenter, open-labeled, non-comparative pharmacokinetic study conducted in 10 critically ill, anuric patients receiving CVVHDF. Enrollment will take place at 3-5 clinical sites in the United States.
- Trial name
- NCT00573898
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Pittsburgh
End-stage Renal Disease, Renal Failure Chronic Requiring Hemodialysis
Study to Evaluate Daptomycin Given During Dialysis and After Dialysis
The purpose of this study is to determine whether daptomycin at a higher dose given during the last 30 minutes of a dialysis session is equal to a lower dose of daptomycin given after a dialysis session.
- Trial name
- NCT00882557
- Testing
- daptomycin
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Wound Infection
Daptomycin as Antibiotic Prophylaxis of Sternal Wound Infections
The purpose of this study is to show that the incidence of sternal wound infections at day 30 after cardiac surgery is 50% lower with the additional use of Daptomycin on top of a standard antibiotic prophylaxis as compared to the…
- Trial name
- DaPro (NCT01080963)
- Testing
- Daptomycin, Cefuroxime
- Where
- Germany
- Volunteers
- 650 people
- Sponsor
- Hannover Medical School
Antibiotics Causing Adverse Effects in Therapeutic Use
Utility Assessment of a Pharmacy-to-Dose Daptomycin
A pharmacy-to-dose (PTD) service, also referred to as pharmacy-based dosing, describes an established practice where providers can consult pharmacists for the dosing of various medications.
- Trial name
- NCT05224687
- Testing
- Retroactive review of patient data of those receiving a dose of daptomycin
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Methodist Health System
Infective Endocarditis, Infection Related to Ventricular Assist Device
Retrospective Analysis of Nephrotoxicity During Daptomycin Versus Vancomycin Treatments in High Risk Patients
Acute kidney injury (AKI) is a frequent complication that occurs in 15 to 25% of patients after vascular surgery, and up to 40% of patients after cardiac surgery.
- Conditions
- Infective Endocarditis, Infection Related to Ventricular Assist Device, Infection Related to Vascular Prothesis, Surgical Site Infection
- Trial name
- DVN (NCT03961503)
- Testing
- Daptomycin (DAP) treatment, Vancomycin (VAN) treatment
- Where
- France
- Volunteers
- 72 people
- Sponsor
- University Hospital, Montpellier
Methicillin Susceptible Staphylococcus Aureus Septicemia, Bacteremia
Daptomycin as Adjunctive Therapy for Staphylococcus Aureus Bacteremia
The purpose of our study is to examine the effects of a second antibiotic, daptomycin, in combination with a beta lactam antibiotic on treating bloodstream infection caused by methicillin-susceptible S. aureus.
- Trial name
- DASH (NCT02972983)
- Testing
- Daptomycin
- Where
- Canada
- Volunteers
- 102 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Critically Ill, Hemodialysis
Pharmacokinetics of Daptomycin in Critically Ill Patients Receiving Continuous Venovenous Hemodialysis (CVVHD)
Daptomycin is an antibiotic that is affective against many strains of antibiotic resistant microorganisms. This antibiotic would be appropriate for use in the intensive care unit (ICU) considering the severity of illness and high…
- Trial name
- NCT00663403
- Testing
- Daptomycin
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Michigan
Antibiotic
The Efficacy and Safety of Daptomycin in the Treatment of Gram-positive Bacterial Infection.
This study aims to collect and analyze clinical data of daptomycin to explore the efficacy and safety of daptomycin in the treatment of Gram-positive bacterial infections. And optimize the dosing regimen based on these data.
- Trial name
- NCT04546815
- Testing
- Daptomycin
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Jiangsu Hengrui Pharmaceutical Co., Ltd.
Septic Shock
The Pharmacokinetics/Pharmacodynamics of High-dose Daptomycin in Patients With Septic Shock
The first objective of this study was to characterize the pharmacokinetics and pharmacodynamics of daptomycin with a daily dose of 12mg/kg in septic shock patient; the second objective is to identify the optimal dosing scheme for…
- Trial name
- NCT02508350
- Testing
- Daptomycin, determination of plasma concentration
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Zhongda Hospital